Colistin resistance in Klebsiella pneumoniae

International Journal of Antimicrobial Agents

Volumn 44, Issue 1, 2014, Pages 8-15

  Ah, Young Mi ^a   Kim, Ah Jung ^b   Lee, Ju Yeun ^a  

^a Hanyang University   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Colistin; Epidemiology; Klebsiella pneumoniae; Microbial resistance; Multidrug resistance

Indexed keywords

AMIKACIN; AZTREONAM; CARBAPENEM; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE; ANTIINFECTIVE AGENT; BETA LACTAMASE; LIPOPOLYSACCHARIDE;

ANTIBIOTIC RESISTANCE; COLISTIN RESISTANT KLEBSIELLA PNEUMONIAE; DISEASE ACTIVITY; DISEASE ASSOCIATION; INCIDENCE; INFECTION RISK; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; TREATMENT PLANNING; CHEMISTRY; CROSS INFECTION; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; KLEBSIELLA INFECTIONS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PHYSIOLOGY; TRANSMISSION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; COLISTIN; CROSS INFECTION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LIPOPOLYSACCHARIDES; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME;

EID: 84902551410     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.02.016     Document Type: Short Survey

References (75)

1. H. Knothe, P. Shah, V. Krcmery, M. Antal, and S. Mitsuhashi Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens Infection 11 1983 315 317
2. J.D.D. Pitout, and K.B. Laupland Extended-spectrum β-lactamase- producing Enterobacteriaceae: an emerging public-health concern Lancet Infect Dis 8 2008 159 166
3. C. Mugnaioli, F. Luzzaro, F. De Luca, G. Brigante, M. Perilli, and G. Amicosante et al. CTX-M-type extended-spectrum β-lactamases in Italy: molecular epidemiology of an emerging countrywide problem Antimicrob Agents Chemother 50 2006 2700 2706
4. T. Naas, and P. Nordmann Analysis of a carbapenem-hydrolyzing class A β-lactamase from Enterobacter cloacae and of its LysR-type regulatory protein Proc Natl Acad Sci USA 91 1994 7693 7697
5. D. van Duin, K.S. Kaye, E.A. Neuner, and R.A. Bonomo Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes Diagn Microbiol Infect Dis 75 2013 115 120
6. N. Gupta, B.M. Limbago, J.B. Patel, and A.J. Kallen Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention Clin Infect Dis 53 2011 60 67
7. P.J. Bergen, J. Li, C.R. Rayner, and R.L. Nation Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa Antimicrob Agents Chemother 50 2006 1953 1958
8. P. Beringer The clinical use of colistin in patients with cystic fibrosis Curr Opin Pulm Med 7 2001 434 440
9. D. Landman, C. Georgescu, D.A. Martin, and J. Quale Polymyxins revisited Clin Microbiol Rev 21 2008 449 465
10. H. Giamarellou Colistin: the loss of the last frontier? APUA Newsl 25 2007 5
11. G. Meletis, E. Tzampaz, E. Sianou, I. Tzavaras, and D. Sofianou Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae J Antimicrob Chemother 66 2011 946 947
12. T.Y. Tan, and S.Y. Ng Comparison of Etest, Vitek and agar dilution for susceptibility testing of colistin Clin Microbiol Infect 13 2007 541 544
13. G. Samonis, D.K. Matthaiou, D. Kofteridis, S. Maraki, and M.E. Falagas In vitro susceptibility to various antibiotics of colistin-resistant Gram-negative bacterial isolates in a general tertiary hospital in Crete, Greece Clin Infect Dis 50 2010 1689 1691
14. A.P. Magiorakos, A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, and C.G. Giske et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Clin Microbial Infect 18 2012 268 281
15. I.K. Neonakis, G. Samonis, H. Messaritakis, S. Baritaki, A. Georgiladakis, and S. Maraki et al. Resistance status and evolution trends of Klebsiella pneumoniae isolates in a university hospital in Greece: ineffectiveness of carbapenems and increasing resistance to colistin Chemotherapy 56 2010 448 452
16. F. Kontopidou, D. Plachouras, E. Papadomichelakis, G. Koukos, I. Galani, and G. Poulakou et al. Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients Clin Microbiol Infect 17 2011 E9 E11
17. J.Y. Suh, J.S. Son, D.R. Chung, K.R. Peck, K.S. Ko, and J.H. Song Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea Antimicrob Agents Chemother 54 2010 560 562
18. T.Y. Tan, and S.Y. Ng The in-vitro activity of colistin in Gram-negative bacteria Singapore Med J 47 2006 621 624
19. A. Walkty, M. DeCorby, K. Nichol, J.A. Karlowsky, D.J. Hoban, and G.G. Zhanel In vitro activity of colistin (polymyxin E) against 3,480 isolates of Gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008 Antimicrob Agents Chemother 53 2009 4924 4926
20. A.C. Gales, R.N. Jones, and H.S. Sader Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09) J Antimicrob Chemother 66 2011 2070 2074
21. A. Poudyal, B.P. Howden, J.M. Bell, W. Gao, R.J. Owen, and J.D. Turnidge et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae J Antimicrob Chemother 62 2008 1311 1318
22. G. Samonis, S. Maraki, D.E. Karageorgopoulos, E.K. Vouloumanou, and M.E. Falagas Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates Eur J Clin Microbiol Infect Dis 31 2012 695 701
23. K. Pontikis, I. Karaiskos, S. Bastani, G. Dimopoulos, M. Kalogirou, and M. Katsiari et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria Int J Antimicrob Agents 43 2014 52 59
24. V. Strenger, T. Gschliesser, A. Grisold, G. Zarfel, G. Feierl, and L. Masoud et al. Orally administered colistin leads to colistin-resistant intestinal flora and fails to prevent faecal colonisation with extended-spectrum β-lactamase-producing enterobacteria in hospitalised newborns Int J Antimicrob Agents 37 2011 67 69
25. T. Halaby, N. Al Naiemi, J. Kluytmans, J. van der Palen, and C.M. Vandenbroucke-Grauls Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit Antimicrob Agents Chemother 57 2013 3224 3229
26. M. Souli, F.V. Kontopidou, E. Papadomichelakis, I. Galani, A. Armaganidis, and H. Giamarellou Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-β-lactamase in a Greek university hospital Clin Infect Dis 46 2008 847 854
27. S. Chen, F. Hu, X. Zhang, X. Xu, Y. Liu, and D. Zhu et al. Independent emergence of colistin-resistant Enterobacteriaceae clinical isolates without colistin treatment J Clin Microbiol 49 2011 4022 4023
28. M. Souli, I. Galani, A. Antoniadou, E. Papadomichelakis, G. Poulakou, and T. Panagea et al. An outbreak of infection due to β-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes Clin Infect Dis 50 2010 364 373
29. A. Toth, I. Damjanova, E. Puskas, L. Janvari, M. Farkas, and A. Dobak et al. Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary Eur J Clin Microbiol Infect Dis 29 2010 765 769
30. A. Capone, M. Giannella, D. Fortini, A. Giordano, M. Meledandri, and M. Ballardini et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality Clin Microbiol Infect 19 2013 E23 E30
31. S. Mezghani Maalej, M. Rekik Meziou, F. Mahjoubi, and A. Hammami Epidemiological study of Enterobacteriaceae resistance to colistin in Sfax (Tunisia) Med Mal Infect 42 2012 256 263
32. M.E. Falagas, G.C. Makris, G. Dimopoulos, and D.K. Matthaiou Heteroresistance: a concern of increasing clinical significance? Clin Microbiol Infect 14 2008 101 104
33. M. Lamousin-White, and R.J. O'Callaghan Association between colistin resistance and broad-spectrum recipient deficiency in Klebsiella pneumoniae Antimicrob Agents Chemother 30 1986 964 965
34. D.K. Matthaiou, A. Michalopoulos, P.I. Rafailidis, D.E. Karageorgopoulos, V. Papaioannou, and G. Ntani et al. Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: a matched case-control study Crit Care Med 36 2008 807 811
35. J. Hrabak, J. Niemczykova, E. Chudackova, M. Fridrichova, V. Studentova, and D. Cervena et al. KPC-2-producing Klebsiella pneumoniae isolated from a Czech patient previously hospitalized in Greece and in vivo selection of colistin resistance Folia Microbiol (Praha) 56 2011 361 365
36. T. Bogdanovich, J.M. Adams-Haduch, G.B. Tian, M.H. Nguyen, E.J. Kwak, and C.A. Muto et al. Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258 Clin Infect Dis 53 2011 373 376
37. A.J. Brink, J. Coetzee, C. Corcoran, C.G. Clay, D. Hari-Makkan, and R.K. Jacobson et al. Emergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South Africa and evidence of in vivo selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tract J Clin Microbiol 51 2013 369 372
38. J. Li, K. Coulthard, R. Milne, R.L. Nation, S. Conway, and D. Peckham et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis J Antimicrob Chemother 52 2003 987 992
39. J. Li, C.R. Rayner, R.L. Nation, R. Deans, R. Boots, and N. Widdecombe et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration Antimicrob Agents Chemother 49 2005 4814 4815
40. K.H. Lin, Y.C. Chuang, S.H. Lee, and W.L. Yu In vitro synergistic antimicrobial effect of imipenem and colistin against an isolate of multidrug-resistant Enterobacter cloacae J Microbiol Immunol Infect 43 2010 317 322
41. Z.Z. Deris, H.H. Yu, K. Davis, R.L. Soon, J. Jacob, and C.K. Ku et al. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model Antimicrob Agents Chemother 56 2012 5103 5112
42. P.J. Bergen, J. Li, R.L. Nation, J.D. Turnidge, K. Coulthard, and R.W. Milne Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model J Antimicrob Chemother 61 2008 636 642
43. V. Savini, C. Catavitello, M. Talia, A. Balbinot, F. Febbo, and A. Pompilio et al. Isolation of colistin-resistant Hafnia alvei J Med Microbiol 58 2009 278 280
44. D. Marchaim, T. Chopra, J.M. Pogue, F. Perez, A.M. Hujer, and S. Rudin et al. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan Antimicrob Agents Chemother 55 2010 593 599
45. S.M. Arduino, M.P. Quiroga, M.S. Ramirez, A.K. Merkier, L. Errecalde, and A. Di Martino et al. Transposons and integrons in colistin-resistant clones of Klebsiella pneumoniae and Acinetobacter baumannii with epidemic or sporadic behaviour J Med Microbiol 61 2012 1417 1420
46. O. Zarkotou, S. Pournaras, E. Voulgari, G. Chrysos, A. Prekates, and D. Voutsinas et al. Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study J Clin Microbiol 48 2010 2271 2274
47. C. Mammina, C. Bonura, F. Di Bernardo, A. Aleo, T. Fasciana, and C. Sodano et al. Ongoing spread of colistin-resistant Klebsiella pneumoniae in different wards of an acute general hospital, Italy, June to December 2011 Euro Surveill 17 2012 pii: 20248
48. P.J. Bergen, C.B. Landersdorfer, J. Zhang, M. Zhao, H.J. Lee, and R.L. Nation et al. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? Diagn Microbiol Infect Dis 74 2012 213 223
49. A. Cannatelli, M.M. D'Andrea, T. Giani, V. Di Pilato, F. Arena, and S. Ambretti et al. In vivo emergence of colistin resistance in Klebsiella pneumoniae producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP mgrB regulator Antimicrob Agents Chemother 57 2013 5521 5526
50. J.S. Gunn, K.B. Lim, J. Krueger, K. Kim, L. Guo, and M. Hackett et al. PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance Mol Microbiol 27 1998 1171 1172
51. S.D. Breazeale, A.A. Ribeiro, and C.R. Raetz Origin of lipid A species modified with 4-amino-4-deoxy-l-arabinose in polymyxin-resistant mutants of Escherichia coli. An aminotransferase (ArnB) that generates UDP-4-deoxyl-l- arabinose J Biol Chem 278 2003 24731 24739
52. M.L. Mezzatesta, F. Gona, C. Caio, V. Petrolito, D. Sciortino, and A. Sciacca et al. Outbreak of KPC-3-producing, and colistin-resistant, Klebsiella pneumoniae infections in two Sicilian hospitals Clin Microbiol Infect 17 2011 1444 1447
53. M.E. Falagas, I.A. Bliziotis, S.K. Kasiakou, G. Samonis, P. Athanassopoulou, and A. Michalopoulos Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria BMC Infect Dis 5 2005 24
54. P. Beno, V. Krcmery, and A. Demitrovicova Bacteraemia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin Clin Microbiol Infect 12 2006 497 498
55. A. Antoniadou, F. Kontopidou, G. Poulakou, E. Koratzanis, I. Galani, and E. Papadomichelakis et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster J Antimicrob Chemother 59 2007 786 790
56. M.E. Falagas, P.I. Rafailidis, D.K. Matthaiou, S. Virtzili, D. Nikita, and A. Michalopoulos Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients Int J Antimicrob Agents 32 2008 450 454
57. K. Kontopoulou, E. Protonotariou, K. Vasilakos, M. Kriti, A. Koteli, and E. Antoniadou et al. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 β-lactamase resistant to colistin J Hosp Infect 76 2010 70 73
58. R.M. Humphries, T. Kelesidis, J. Dien Bard, K.W. Ward, D. Bhattacharya, and M.A. Lewinski Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin J Med Microbiol 59 2010 1383 1386
59. C.H. Tan, J. Li, and R.L. Nation Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model Antimicrob Agents Chemother 51 2007 3413 3415
60. O. Zusman, T. Avni, L. Leibovici, A. Adler, L. Friberg, and T. Stergiopoulou et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems Antimicrob Agents Chemother 57 2013 5104 5111
61. M.G. Jernigan, E.G. Press, M.H. Nguyen, C.J. Clancy, and R.K. Shields The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae Antimicrob Agents Chemother 56 2012 3395 3398
62. M. Souli, P.D. Rekatsina, Z. Chryssouli, I. Galani, H. Giamarellou, and K. Kanellakopoulou Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-β-lactamase-producing Klebsiella pneumoniae isolates? Antimicrob Agents Chemother 53 2009 2133 2135
63. M. Souli, I. Galani, S. Boukovalas, M.G. Gourgoulis, Z. Chryssouli, and K. Kanellakopoulou et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development Antimicrob Agents Chemother 55 2011 2395 2397
64. C. Tascini, E. Tagliaferri, T. Giani, A. Leonildi, S. Flammini, and B. Casini et al. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae Antimicrob Agents Chemother 57 2013 3990 3993
65. C. Vidaillac, L. Benichou, and R.E. Duval In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates Antimicrob Agents Chemother 56 2012 4856 4861
66. K.N. Agwuh, and A. MacGowan Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines J Antimicrob Chemother 58 2006 256 265
67. B.A. Cunha Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis J Clin Microbiol 47 2009 1613
68. I. Galani, M. Souli, G.L. Daikos, Z. Chrysouli, G. Poulakou, and M. Psichogiou et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp, from Athens, Greece J Chemother 24 2012 191 194
69. D.M. Livermore, S. Mushtaq, M. Warner, J.C. Zhang, S. Maharjan, and M. Doumith et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates J Antimicrob Chemother 66 2011 48 53
70. S.M. Drawz, K.M. Papp-Wallace, and R.A. Bonomo New β-lactamase inhibitors: a therapeutic renaissance in an MDR world Antimicrob Agents Chemother 58 2014 1835 1846
71. ® Bioorg Med Chem Lett 24 2014 780 785
72. S. Mushtaq, M. Warner, G. Williams, I. Critchley, and D.M. Livermore Activity of chequerboard combinations of ceftaroline and NXL104 versus β-lactamase-producing Enterobacteriaceae J Antimicrob Chemother 65 2010 1428 1432
73. D.M. Livermore, S. Mushtaq, M. Warner, J. Zhang, S. Maharjan, and M. Doumith et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae Antimicrob Agents Chemother 55 2011 390 394
74. H.S. Sader, M. Castanheira, R.K. Flamm, D.J. Farrell, and R.N. Jones Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from US medical centers in 2012 Antimicrob Agents Chemother 58 2014 1684 1692
75. D.M. Livermore, and S. Mushtaq Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae J Antimicrob Chemother 68 2013 1825 1831